GERN Stock Analysis: Buy, Sell, or Hold?
GERN - Geron Corp
$1.52
-0.03 (-1.94%)
âŧ
5d:
+3.4%
30d:
+4.83%
90d:
+20.63%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 05, 2026
0d
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Aug 19, 2026 at $1.59 · last confirmed Aug 21, 2026
Strength: 4.3/10
Get Alerted When GERN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: GERN is fairly priced but lacks strong directional signals. At 19.5% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: GERN is fairly priced but lacks strong directional signals. At 19.5% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: GERN is currently trading at $1.52, which is considered slightly high relative to its 30-day fair value range of $1.37 to $1.55. From a valuation perspective, the stock is trading at a premium (Forward PE: 38.0) compared to its historical average (22.2). At these levels, the market is pricing in 19.5% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, GERN is in a downtrend. Immediate support is located at $1.43, while resistance sits at $1.65.
Market Sentiment: GERN scores 13/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.25 (+179.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GERN is in a downtrend. Immediate support is located at $1.43, while resistance sits at $1.65.
Market Sentiment: GERN scores 13/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.25 (+179.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$1.37 -
$1.55
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
41.9%
Protect Your Profits
Holding GERN? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Weak technical setup (13/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 179.6% below Wall St target ($4.25)
- NEUTRAL: Trading at premium valuation - market expects 19.5% growth which is achievable
- WARNING: Composite score 42/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.37 -
$1.55
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$1.43
Resistance Level
$1.65
Current Trend
Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
38.00
Wall Street Target
$4.25
(+179.6%)
Revenue Growth (YoY)
17.2%
Profit Margin
-33.1%
Valuation Premium vs History
+19.5% premium
PE vs Historical
38.0 vs 22.2
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+19.5%
(market-implied from PE analysis)
1-Year Target
$1.82
(+20%)
2-Year Target
$2.17
(+43%)
3-Year Target
$2.59
(+71%)
3-Yr Target (if PE normalizes)
(PE: 38â22)
PE COMPRESSION
$1.52
(0%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: August 23, 2026 7:47 AM ET
Data refreshes hourly during market hours. Next update: 8:47 AM
Data refreshes hourly during market hours. Next update: 8:47 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GERN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals âĻ |
STRONG BUY
30 analysts |
$372 | 42 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 27 SELL |
|
VRTX
Vertex Pharmaceuticals IâĻ |
BUY
34 analysts |
$563 | 30 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$309 | 51 HOLD |
|
APLS
Apellis Pharmaceuticals âĻ |
BUY
22 analysts |
$41 | 50 HOLD |
Advanced GERN Option Strategies
Professional options setups generated by AI based on today's GERN price and gamma walls.
